Department of Medical Oncology, Tianjin Medical University General Hospital, Tianjin, China.
Department of Lung Cancer, Tianjin Lung Cancer Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
J Int Med Res. 2022 Oct;50(10):3000605221128092. doi: 10.1177/03000605221128092.
To evaluate clinical factors influencing the postoperative pulmonary sarcomatoid carcinoma (PSCs) prognosis.
We retrospectively evaluated patients with PSCs treated from October 2012 to October 2017. Kaplan-Meier survival curves were calculated using univariable analysis (log-rank test). Univariable/multivariable Cox regression analysis was also performed.
Mixed PSCs were most common (64.10%). Pure PSCs occurred more often with large tumors compared with mixed PSCs. Patients with vs without pleural retraction, respectively, had significantly worse overall survival (OS; 16 vs 23 months) and disease-free survival (DFS; 11 vs 20 months), and patients with airway dissemination had significantly shorter OS (14 vs 21 months) and DFS (11 vs 20 months). Patients with PSC with an adenocarcinoma component had favorable OS. Airway dissemination, pleural retraction, metastatic mediastinal lymph node (LN) number, and pathological tumor-node-metastasis (pTNM) stage were risk factors for short OS. Neither adjuvant chemotherapy nor adjuvant radiotherapy provided a survival advantage. Airway dissemination was an independent prognostic factor (odds ratio, 1.87; 95% confidence interval, 1.04-3.36).
Pure PSCs were more likely with large tumors compared with mixed PSCs. Airway dissemination, pleural retraction, and metastatic mediastinal LN number were associated with OS. Airway dissemination was an independent prognostic factor.
评估影响肺肉瘤样癌(PSCs)术后预后的临床因素。
我们回顾性评估了 2012 年 10 月至 2017 年 10 月期间接受治疗的 PSCs 患者。使用单变量分析(对数秩检验)计算 Kaplan-Meier 生存曲线。还进行了单变量/多变量 Cox 回归分析。
混合 PSCs 最常见(64.10%)。与混合 PSCs 相比,纯 PSCs 更常发生于大肿瘤患者。与无胸膜回缩的患者相比,有胸膜回缩的患者总生存期(OS;16 个月 vs 23 个月)和无病生存期(DFS;11 个月 vs 20 个月)明显更差,气道播散的患者 OS(14 个月 vs 21 个月)和 DFS(11 个月 vs 20 个月)明显更短。具有腺癌成分的 PSC 患者 OS 良好。气道播散、胸膜回缩、转移性纵隔淋巴结(LN)数量和病理肿瘤-淋巴结-转移(pTNM)分期是 OS 较短的危险因素。辅助化疗和辅助放疗均不能带来生存优势。气道播散是独立的预后因素(优势比,1.87;95%置信区间,1.04-3.36)。
与混合 PSCs 相比,纯 PSCs 更可能发生于大肿瘤患者。气道播散、胸膜回缩和转移性纵隔 LN 数量与 OS 相关。气道播散是独立的预后因素。